Immuron exceeded the sales expectations established during its strategic reset as fiscal 2026 revenue reached a record level, U.S. sales continued expanding and the biotechnology company’s cash position increased substantially.
Fiscal 2026 net sales reached a record A$7.7 million, increasing 6% from the prior-year period.
Second-half sales increased 7%.
The results exceeded the expectations Immuron had communicated in February when it launched its Strategic Reset and projected both second-half and full-year sales growth.
The company’s Australian operation remained the largest source of commercial momentum.
Australian sales increased 10% despite what Immuron described as a one-time inventory reduction by Chemist Warehouse/Sigma related to supply-chain efficiency initiatives.
That makes the double-digit domestic growth notable because sales absorbed a temporary distributor inventory headwind during the year.
The United States also continued expanding.
U.S. sales increased 7% when measured in Australian dollars and 13% in U.S. dollars, supported by a series of marketing initiatives.
Canadian revenue was lower for the full year, but second-half sales increased by more than 100% from the prior-year period.
Immuron’s commercial business centers on Travelan, its orally administered product targeting travelers’ diarrhea.
In Australia, Travelan is listed on the Australian Register for Therapeutic Goods and indicated to reduce the risk of travelers’ diarrhea and minor gastrointestinal disorders.
In Canada, it is licensed as a natural health product, while in the U.S. it is sold as a dietary supplement for digestive-tract protection.
Improvement was not limited to revenue.
Immuron said fiscal 2026 net profit improved by A$1.4 million compared with fiscal 2025.
More importantly for a small biotechnology company with development-stage programs, liquidity increased substantially.
Cash increased by A$6.2 million to A$9 million at June 30.
The larger cash position gives Immuron additional flexibility as it balances investment in the commercial Travelan franchise with its clinical-development assets.
Those assets also reached several milestones during fiscal 2026.
The U.S. FDA approved the investigational new drug application for IMM-529 in November 2025.
That program targets recurrent Clostridioides difficile infection and is ready to advance into Phase 2 clinical testing.
Immuron has chosen to pursue a partnering strategy for both IMM-529 and IMM-124E rather than bear all future development and commercialization costs itself.
The company engaged Pullan Consulting in July 2026 to support the IMM-529 partnering process.
IMM-124E is eligible for an end-of-Phase-2 meeting with the FDA for the travelers’ diarrhea indication.
Immuron cited external Lumanity estimates of potential peak U.S. sales of $400 million for IMM-529 and $102 million for IMM-124E.
Those figures are third-party commercial estimates rather than company revenue forecasts, and both programs would still need to successfully complete additional clinical and regulatory development before potential commercialization.
The company’s research platform also received support from the U.S. defense ecosystem.
A research agreement funded through a U.S. Department of Defense sub-award with the Naval Medical Research Command and Walter Reed Army Institute of Research covers development of vaccine approaches targeting Campylobacter and Shigella.
Immuron is producing two hyper-immune bovine colostrum products for preclinical evaluation under the program, and the company received its first revenue from the project in May 2026.
That creates an additional source of externally funded development activity alongside the company’s commercial products.
For fiscal 2027, Immuron plans to invest behind further North American growth while maintaining momentum in Australia.
Its stated milestones include continued Travelan growth in Q1, portfolio expansion in Q2, progress toward an IMM-529 partnership during Q3, and geographic expansion combined with improved profitability and lower cash burn in Q4.
The positive story is therefore broader than the 6% increase in annual sales.
Immuron delivered record revenue, grew the Australian business at a double-digit rate, increased U.S.-dollar sales by 13%, substantially improved its cash position and moved IMM-529 into a Phase-2-ready position.
At the same time, its decision to seek partners for its two principal clinical assets could potentially reduce the amount of internal capital required to advance those programs.
For a small biotech-commercial hybrid, that combination of higher product revenue, increased cash and a partnering-oriented development model provides a stronger financial foundation entering fiscal 2027.
